Updates are available Correction dated 2024-12-11
Click to view Correction: https://doi.org/10.1007/s40262-024-01458-0
-
Authors
Zhang, Daping
Taylor, Adekemi
Zhao, Jie Janet
Endres, Christopher J.
Topletz-Erickson, Ariel https://orcid.org/0000-0002-8909-4685
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03723395 at ClinicalTrials.govnct03914755 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
https://doi.org/10.1007/s40262-022-01144-z
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
nct03826602 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
nct03043313 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
nct01983501 at ClinicalTrials.govDocuments that mention this clinical trial
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
https://doi.org/10.1200/jco.2023.41.16_suppl.3528
HER2 testing in colorectal cancer: Concordance analysis between breast and gastric scoring algorithms from the MOUNTAINEER trial.
https://doi.org/10.1200/jco.2023.41.4_suppl.198
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).
https://doi.org/10.1200/jco.2024.42.16_suppl.3509
nct02025192 at ClinicalTrials.govDocuments that mention this clinical trial
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
Documents that mention this clinical trial
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
https://doi.org/10.1007/s40262-024-01412-0
-
Funding
Funding for this research was provided by:
This study was sponsored by Seagen which was acquired by Pfizer in December 2023
- License Information
-
More Information
Article History
Accepted: 8 August 2024
First Online: 5 October 2024
Change Date: 27 November 2024
Change Type: Update
Change Details: The original online version of this article was revised to correct an entry in Table 2.
Change Date: 11 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40262-024-01458-0
Declarations
:
: This study was sponsored by Seagen, which was acquired by Pfizer Inc. in December 2023.
: Daping Zhang, Christopher J. Endres, and Ariel Topletz-Erickson are employees of Pfizer Inc. Adekemi Taylor and Jie Janet Zhao are employees of Certara USA, which was a paid consultant to Pfizer Inc. in connection with the development of this manuscript.
: All studies were conducted in accordance with the Declaration of Helsinki and the International Conference of Harmonization Guideline for Good Clinical Practice. All studies were approved by an institutional review board or ethics committee at each site.
: All participants provided written informed consent for study-related treatments and procedures.
: Not applicable.
: Upon request, and subject to review, Pfizer Inc. will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer Inc. may also provide access to the related individual de-identified participant data. See for more information.
: The model code is available in the supplemental material.
: All authors contributed to the analysis and interpretation of data. All authors contributed to critical reviews and revisions of the article and provided their final approval for publication.
